Immune-related adverse event (irAE) education, self-efficacy, and potential irAE experiences in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).

Mujumdar, U; Wang, HF; Lawler, E; Lanzarini, V; Lowe, M; Trunova, N; Klein, AB; Emmas, C

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (8):